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Letter to the Editor: Brief Case Report

Parotid Gland
Enlargement
Associated With
Clonazepam: A
Case Report
TO THE EDITOR: Xerostomia is a
commonly reported side effect of many
psychiatric medications including benzodiazepines. Xerostomia can also be
present in the potentially common but
less frequently identiﬁed condition of
burning mouth syndrome. Clonazepam has been associated with exacerbation of xerostomia, but also,
paradoxically, with alleviation of
burning mouth syndrome.1 Indeed, the
interactions between benzodiazepines
and salivary gland dysfunctions are not
well understood.
Several investigations have
shown that in rodent parotid glands,
diazepam and clonazepam reduce
salivary secretion.2,3 Long-term
exposure of the rat parotid gland to
diazepam has been shown to result in
salivary retention and enlarged
mass.4 We searched PubMed and
Embase to identify human correlates
of parotid gland enlargement in
response to either clonazepam or
diazepam; however, we were unable
to identify deﬁnitive cases.
To the best of our knowledge,
we present the ﬁrst reported case of a
young man who experienced bilateral parotid gland enlargement
associated with clonazepam.
CASE PRESENTATION
Alex is a 25-year-old South Asian
man with autism spectrum disorder,

generalized anxiety disorder, and
intermittent explosive disorder. An
initial trial of sertraline in March
2020 was followed by extreme
disinhibition and psychiatric hospitalization at which time sertraline
was discontinued. During his hospitalization, other symptoms indicative
of substance-induced or bipolar
mania did not emerge; trial of
another serotonin modulator, buspirone, produced similar disinhibition without other symptoms of
mania.
Later that month, we initiated
valproic acid to target intermittent
explosive disorder and aggression.
Valproic acid was titrated further
over several months; however, he
was unable to tolerate doses greater
than 250 mg b.i.d. owing to lethargy
and tremors. As aggression with
potential to harm others persisted
through August 2020, valproic acid
was augmented with risperidone
(titrated to 1 mg nightly).
Unfortunately, aggression worsened (most likely due to akathisia).
Therefore, risperidone was replaced
with olanzapine 5 mg nightly. As he
continued to struggle with generalized anxiety disorder, he was also
initiated on clonazepam 0.25 mg
daily.
In early October 2020, his
mother noticed left cheek swelling.
His primary care physician suspected
parotitis; swelling resolved with
clindamycin.
By November 2020, he reported
intolerable sialorrhea which was
managed well with ipratropium
0.06% spray. Aside from sialorrhea,
he demonstrated euthymia without

aggression for the subsequent 2
months, and in January 2021, we
discontinued valproic acid.
In late January 2021, his mother
noticed bilateral cheek swelling.
Concurrently, aggression relapsed
but his mother requested to avoid
VPA. We suspected the swelling was
due to olanzapine and we therefore
replaced it with aripiprazole. Unfortunately, aripiprazole caused intolerable nausea and we reinitiated
risperidone at a lower dose (0.5 mg
daily).
Aggression improved considerably; but, by early March 2021,
bilateral face swelling was not
improved. We began to suspect an
association with clonazepam and
tapered it over March 2021. In April
2021, there was greater than 50%
improvement. On surgical evaluation, there is concern parotid gland
swelling may not fully resolve.
DISCUSSION
In rats, benzodiazepines decrease
salivary secretion from the parotid
gland through agonist activity at
central-type and peripheral-type
benzodiazepine receptors. Diazepam exhibits agonist activity at
central-type and peripheral-type
benzodiazepine receptors, whereas
clonazepam demonstrates activity at
only central-type benzodiazepine
receptors.2,3
Because diazepam is an agonist at
multiple benzodiazepine receptors, it
may induce greater salivary dysfunction than clonazepam. Indeed, both
diazepam and clonazepam demonstrate reduction in pilocarpine
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stimulated salivary secretion in the
parotid gland of rats,4 whereas salivary secretion may be more strongly
inhibited by diazepam.5
The case presented herein suggests
that there are potential human correlates of benzodiazepine-associated
salivary gland dysfunction. Peripheral-type benzodiazepine receptors are
not limited to rodents; more recently,
peripheral-type benzodiazepine receptors have also been identiﬁed in
human salivary glands using photolabeling with receptor ligands3 as well
as with positron emission tomography.6 We suggest that speciﬁc benzodiazepines may distinctively affect
salivary gland dysfunction through
disparate mechanisms such as variability in drug-receptor interactions as
previously mentioned. These warrant
further study and may have signiﬁcant
clinical impact; for example, switching
from clonazepam to diazepam may
exacerbate parotid gland dysmorphia.
There are several limitations
that must be considered. Although
we report an association between
clonazepam and parotid gland
enlargement, we cannot prove causality. There were also several medication trials which could have also
inﬂuenced salivary dysfunction such
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as olanzapine. However, parotid
gland enlargement only improved
after clonazepam was discontinued.
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